About Keyan Salari, MD, PhD

Keyan Salari, MD, PhD is a urologic oncologist at the Massachusetts General Hospital Department of Urology and Harvard Medical School. He is a urologic surgeon specialized in the treatment of genitourinary cancers using open, laparoscopic, and robotic surgery techniques. His research focuses on applying cancer genomics and computational biology methods to advance precision cancer medicine for genitourinary malignancies. 

Dr. Salari is a faculty member of the Department of Urology and a Urologic Oncologist at Massachusetts General Hospital. He graduated with honors from the University of California at Berkeley with a B.A. in molecular and cellular biology, where he was awarded the Spencer W. Brown Award for the best undergraduate thesis in genetics and was a Howard Hughes Medical Institute Biology Fellow. He earned his MD and PhD in Genetics from Stanford University School of Medicine in the NIH Medical Scientist Training Program. He trained in General Surgery and Urology at the Massachusetts General Hospital and subsequently completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center.

Dr. Salari’s clinical practice focuses on the surgical treatment of urologic cancers with a particular emphasis on prostate cancer and testicular cancer. His research interests focus on leveraging a variety of genomic technologies and computational biology methods to gain insight into the pathobiology of prostate cancer, with the goal of improving early detection of clinically significant prostate cancer and distinguishing indolent from aggressive disease to guide treatment decisions.

Clinical Interests:




Urology Associates
165 Cambridge St
7th Floor
Boston, MA 02114-2783
Phone: 857-238-3838
Fax: 617-726-6131

MGH Cancer Center
Center for Genitourinary Cancers
55 Fruit Street, Yawkey 7E
Boston, MA 02114
Phone: 617-726-5130

Medical Education

  • PhD, Stanford University
  • MD, Stanford University School of Medicine
  • Residency, Massachusetts General Hospital
  • Fellowship, Memorial Sloan Kettering Cancer Center

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


  • View my most recent publications at PubMed

    • Liu D, Shoag J, Poliak D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020 Apr 24;11(1):1987.
    • Hanna N, Wszolek MF, Mojtahed A, et al. Multiparametric MRI/ultrasound fusion biopsy improves but does not replace standard template biopsy for the detection of prostate cancer. J Urol. 2019 May 30.
    • Salari K, Kuppermann D, Preston MA, et al. Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years. J Urol. 2019 Apr;201(4):721-727.
    • Wang Z, Hu L, Salari K, et al. Androgenic to Estrogenic Switch in Human Adult Prostate Gland as a result of Epigenetic Silencing of Steroid 5-α Reductase 2. J Pathol. 2017 Dec;243(4):457-467.
    • Cuff J, Salari K, Esheba GE, et al. Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS ONE 2013 Sep 9;8(9):e74562.
    • Salari K, Spulak ME, Cuff J, et al. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci USA. 2012 Nov 13;109(46):E3196-205.
    • Huang S, Gulzar ZG, Salari K, et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene. 2012 Sep 13;31(37):4164-70.
    • Salari K, Tibshirani R, Pollack JR. DR-Integrator: a new analytic tool for integrating DNA copy number and gene expression data. Bioinformatics. 2010 Feb 1;26(3):414-6.